VMD earnings analysis
What we found in VMD's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
Viemed delivered Q2 revenue of $78.097 million, up 23.9% year over year and 3.6% sequentially, supported by growth in ventilator, sleep/PAP, resupply and women's-health offerings, including Lehan operations. However, gross margin fell to 57.7% from 58.3%, operating margin declined to 5.7% from 8.1%, and net income attributable to Viemed decreased 12.4% to $2.764 million as SG&A growth and disposal losses outweighed revenue gains. Six-month operating cash flow improved to $23.973 million, but receivables rose $6.6 million and cash ended at $10.680 million; the filing contains no quantitative guidance.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- Revenue growth accelerated to 23.9% YoY
- Q2 revenue rose $15.041 million, or 23.9%, year over year to $78.097 million and increased $2.683 million, or 3.6%, sequentially from $75.414 million in Q1 2026. Growth was broad-based across each reported revenue category.
- Diversification powered sales growth
- Equipment and supply sales nearly doubled, rising $9.457 million, or 99.4%, to $18.971 million, driven by women's-health product sales and higher PAP resupply volumes. Other HME rentals grew $2.585 million, or 18.7%, to $16.408 million.
- Patient census expanded materially
- Patient counts reached 12,635 ventilator patients, 37,825 PAP therapy patients and 37,035 sleep-resupply patients at June 30, 2026. These compare with 12,152, 26,260 and 25,246, respectively, at June 30, 2025.
- Operating cash flow improved strongly
- Six-month operating cash flow increased $8.865 million to $23.973 million from $15.108 million a year earlier. Purchases of property and equipment were $15.151 million, equal to 9.9% of $153.511 million six-month revenue.
- Capital return program remains active
- The company repurchased 680,802 shares during the first six months of 2026 under its 2026 program; 1,249,329 shares remained available at June 30. Q2 purchases totaled 535,260 shares at a $9.65 average price.
- Management sees adequate near-term liquidity
- Liquidity includes $10.680 million of cash, no revolver borrowings and $7.4 million outstanding under the term loan at June 30, 2026. Management believes cash, operating cash flow and facility availability will fund requirements for at least the next 12 months.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- Profitability declined despite revenue growth
- Operating margin contracted 240 basis points year over year to 5.7% from 8.1%, while net income attributable to Viemed declined $0.393 million, or 12.4%, to $2.764 million despite 23.9% revenue growth.
- Mix shift is diluting gross margin
- Gross margin decreased 60 basis points year over year to 57.7% as sales-and-services revenue increased to 32.4% of revenue from 24.4%. Management notes this mix generally carries lower gross margins, albeit lower capital-expenditure needs.
- SG&A growth outpaced revenue
- SG&A rose $8.329 million, or 28.9%, to $37.132 million and reached 47.5% of revenue versus 45.7% a year ago. The increase includes $4.0 million of higher employee compensation, about $0.9 million in phantom-stock compensation and about $0.6 million in sales compensation.
- Prior disposal gains will not recur
- The company recorded a $0.598 million loss on equipment disposal versus a $0.636 million gain in Q2 2025; management says the ventilator buyback program was substantially completed in 2025 and does not expect additional material gains.
- Receivables growth consumed working capital
- Working-capital investment included a $6.6 million increase in net accounts receivable and a $1.7 million increase in prepaid expenses and other assets during the first six months of 2026. Cash declined to $10.680 million at June 30 from $13.501 million at December 31, 2025.
- No new risk-factor disclosures; policy risk persists
- There were no material changes to risk factors from the 2025 Form 10-K, according to Item 1A. Existing policy exposure remains material: CMS issued the final ventilator National Coverage Determination on June 9, 2025, and most OBBBA provisions are scheduled for 2027 and 2028, with some state actions possible in 2026.
What they reported.
What the company itself reported, taken out of the document.
- Gross margin
- 57.7%
- Operating margin
- 5.7%
- Segment
- Ventilator rentals: $36.411 million, +7.7% year over year
- Segment
- Other home medical equipment rentals: $16.408 million, +18.7% year over year
- Segment
- Equipment and supply sales: $18.971 million, +99.4% year over year
- Segment
- Service revenues: $6.307 million, +6.9% year over year
What they said about what is next.
The 10-Q does not provide quantitative revenue or EPS guidance. Management states it expects technology, talent and operating-capacity investments to support future revenue growth and productivity, but says the timing and extent of SG&A leverage depends on when benefits are realized. Quantitative full-year outlook was deferred to the earnings release/call.
The filing reads about the same as the one before it.
What came before.
- 10-Q · May 5, 2026
- Viemed Healthcare, Inc. reported Q1 2026 revenue of $75.4 million, reflecting a significant growth of 27.5% year-over-year, driven by strong demand in the rental and sales of medical equipment. Despite missing EPS…
- 10-K · March 4, 2026
- Viemed positions itself as a technology-enabled, home-based provider focused on respiratory and chronic care, seeking growth by increasing patients served and expanding its licensed clinical workforce. Recent quarterly…
- 10-Q · November 6, 2024
- Viemed reported Q3 revenue of $58.004M (up $8.602M or 17.4% vs Q3 2023 $49.402M) and GAAP diluted EPS of $0.10 (vs $0.07 in Q3 2023). Revenue growth was broad-based (rentals, sales and services) while operating income…
- 10-Q · May 6, 2024
- Viemed reported Q1 revenue of $50.593M (up $11.037M or 27.9% vs Q1 2023 $39.556M) and GAAP diluted EPS of $0.04 (flat vs $0.04 in Q1 2023) while missing the Street EPS estimate ($0.07). Revenue growth was broad-based…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing VMD makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever